The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Insights into the future of the CLL treatment landscape
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, highlights how the chronic lymphocytic leukemia (CLL) treatment landscape will advance in the upcoming years. With non-covalent BTK inhibitors hopefully being approved for use in Europe, there will be an additional treatment option for double-refractory patients. Additionally, these agents could be used in triplet combination regimens to achieve long-term remission for patients with CLL. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
